From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2017 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”转变为“已获批准、指定、列入、合格、注册、报销或预先授权”的买家自身采购、报销、配方、规格、采购、网络、目录或计划系统中的选择——从而公司未来业务的重要部分现在可以在没有每次订单的单独销售事件的情况下到达——并且管理层是否传达了这种准入状态是新的,以至于它解锁的大部分交易量仍领先于报告的结果。 在记录中,管理层讨论了MiFID II的准备,提到MarketAxess的tracks已获得英国FCA批准作为APA和ARM,以及新加坡的RMO批准。这些是监管批准,使公司能够提供交易报告服务。但这是否意味着公司被插入到买方的采购路径中?这些批准使公司能够作为报告服务提供商运营,但并未明确说明公司被列入买方的批准供应商名单或类似系统。管理层还提到“我们的tracks业务应该受益于监管报告义务的增加”,但这是关于公司提供报告服务,而不是公司被列入买方的采购系统。 关于开放交易,管理层提到“开放交易在第三季度创下了客户参与的新纪录”,但这是关于交易量增长,而不是关于被列入买方系统。 关于零售部分,管理层提到“所有零售市场参与者现在都在MarketAxess系统上活跃”,但这是关于客户已经在平台上,而不是关于被列入批准名单。 管理层没有明确描述公司最近被列入买方的采购、报销、配方、规格、网络或目录系统。提到的批准是监管批准,使公司能够提供某些服务,但并未表明公司成为买方默认选择或预先授权。此外,这些批准是公司作为服务提供商的资格,而不是公司被列入买方的采购路径。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.